17,000
UK employees including 15,300 at these sites
Montrose and Irvine
900 employees
Manufacturing
Barnard Castle
1,400
Manufacturing
Ulverston
360
Manufacturing
Ware
2,400
Manufacturing
and research and
development
Stevenage
2,500
Research and
development
Uxbridge
1,700
HQ
Maidenhead
560
Manufacturing
Brentford
4,200
HQ
Worthing
840
Manufacturing
Weybridge
450
Manufacturing
The threat of a no-deal Brexit is forcing a number of companies including GSK, the UK’s biggest drugmaker, to build new laboratories for parallel product testing and shift licences to ensure their products can still be sold in the EU.
The firm, which makes the shingles vaccine Shingrix, is spending up to £70m on a host of measures including securing more warehouse space. A no-deal Brexit could add £50m a year in tariff costs.
GSK says it is making good progress but getting its plans in place before the 29 March deadline is going to be ‘ambitious’.
17,000
Montrose and Irvine
900 employees
Manufacturing
UK employees including 15,300 at these sites
The threat of a no-deal Brexit is forcing a number of companies including GSK, the UK’s biggest drugmaker, to build new laboratories for parallel product testing and shift licences to ensure their products can still be sold in the EU.
The firm, which makes the shingles vaccine Shingrix, is spending up to £70m on a host of measures including securing more warehouse space. A no-deal Brexit could add £50m a year in tariff costs.
GSK says it is making good progress but getting its plans in place before the 29 March deadline is going to be ‘ambitious’.
Edinburgh
Barnard Castle
1,400
Manufacturing
Ware
2,400
Manufacturing
and research and
development
Ulverston
360
Manufacturing
Stevenage
2,500
Research and
development
Uxbridge
1,700
HQ
Uxbridge
1,700
HQ
Brentford
4,200
HQ
Maidenhead
560
Manufacturing
Weybridge
450
Manufacturing
Worthing
840
Manufacturing